Skip to main content

BOSTON (

TheStreet

) -- The October biotech calendar is chock-full of potentially stock moving events, including a dozen drugs facing U.S. approval decisions.

Phase III or pivotal studies that could report results in October:

Oct. 1

FDA drug approval decision:

Hospira'

(HSP)

Dyloject for acute moderate-to-severe pain in adults.

FDA drug approval decisions:

Johnson & Johnson

(JNJ) - Get Johnson & Johnson Report

Nucynta for pain indications.

Oct. 4

FDA drug approval decision:

TheStreet Recommends

Human Genome Sciences'

( HGSI) Zalbin for hepatitis C.

Oct. 8-12

European Society for Medical Oncology annual meeting. Data presentations to include

Johnson & Johnson

(JNJ) - Get Johnson & Johnson Report

(abiraterone),

Oxigene

(OXGN)

(Zybrestat), Seattle Genetics (SGN-75),

Allos Therapeutics

( ALTH) (Folotyn) and

Arqule

(ARQL) - Get ArQule, Inc. Report

(ARQ197).

The Obesity Society annual meeting. Stocks of interest include

Arena Pharmaceuticals

(ARNA) - Get Arena Pharmaceuticals, Inc. Report

,

Vivus

(VVUS) - Get VIVUS, Inc. Report

and

Orexigen Therapeutics

(OREX)

.

Oct. 11

FDA drug approval decision:

Alexza Pharmaceuticals'

(ALXA)

AZ-004 for agitation in patients with schizophrenia or bipolar disorder.

FDA drug approval decision:

Jazz Pharmaceuticals'

(JAZZ) - Get Jazz Pharmaceuticals Public Limited Company Report

JZP-6 for fibromyalgia.

Oct. 12

FDA drug approval decision:

Alkermes

(ALKS) - Get Alkermes Plc Report

Vivitrol for opioid addiction.

Oct 13-16

European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting. Data presentations to include

Sanofi-Aventis

(SNY) - Get Sanofi Report

(Teriflunomide),

Biogen Idec

(BIIB) - Get Biogen Inc. Report

and

Elan

(ELN)

(Tysabri) and

Genzyme

( GENZ) (Campath).

Oct. 18

FDA advisory panel to discuss the use of erythropoeisis-stimulating agents in the treatment of patients with chronic kidney failure.

Amgen

(AMGN) - Get Amgen Inc. Report

(Aranesp, Epogen), Johnson & Johnson (Procrit) and

Affymax

(AFFY)

(Hematide).

Oct. 19

BioMarin Pharmaceuticals

(BMRN) - Get BioMarin Pharmaceutical Inc. Report

analyst/investor day.

Oct. 20

Genzyme third-quarter earnings announcement.

Oct. 22

FDA drug approval decision:

Arena Pharmaceuticals'

(ARNA) - Get Arena Pharmaceuticals, Inc. Report

lorcaserin for obesity

FDA drug approval decision:

Amylin Pharmaceuticals

( AMLN), Alkermes and

Eli Lilly's

(LLY) - Get Eli Lilly and Company Report

Bydureon for diabetes.

Oct. 28

FDA drug approval decision:

Vivus'

(VVUS) - Get VIVUS, Inc. Report

Qnexa for obesity.

Oct. 29

FDA drug approval decision:

Avanir Pharmaceuticals'

(AVNR)

Zenvia for pseudobulbar affect.

FDA drug approval decision:

Forest Labs

(FRX)

ceftaroline for Community Acquired Pneumonia.Oct. 30

FDA drug approval decision:

Biodel's

(BIOD)

Linjeta for diabetes.

Exact Sciences

(EXAS) - Get Exact Sciences Corporation Report

presentation of external validation study of its genetic stool test for colon cancer.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here:

Adam Feuerstein

.

>To follow the writer on Twitter, go to

http://twitter.com/adamfeuerstein

.

>To submit a news tip, send an email to:

tips@thestreet.com

.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.